Mechanism of Action
mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in…
Indications (3)
Clinical Trials (5)
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7378423 | May 29, 2027 | SubstanceProduct | — |
| 7378423*PED | Nov 29, 2027 | — | |
| 8703781 | Oct 15, 2030 | SubstanceProduct | U-2302 |
| 8952018 | Oct 15, 2030 | U-2020 | |
| 8703781*PED | Apr 15, 2031 | — |